Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lol, I'm not in, just watching. Hope u can get out soon...
May break 10 today, strong start.
We get volume here we move big time. This literly moves on air.
Can we stop playing games here and break out of this rut today?
Looking like a very strong day building up. Go PURA, way over due.
Weak news? Lol its freaking huge news, if they find out they can help better a person with COPD and patent it, we fly, we will be rich.
Wow, this is something. GCHK news review, can't believe it, is there something in the grapevine comming?
https://www.bitcoinpriceupdate.review/2019/03/10/stay-cool-with-active-stock-greenchek-technology-inc-otcgchk/
Lol,, up, down, up, down, sideways we go.... When this decides to take off with a killer update, which I know it will be. I will be partying big time cause this will not be a little pop, all that this company is involved in this is no joke, its gonna move very fast, very high... Watch.
Maybe, maybe not. It may not be the companies fault if it was satisfied, according to the update. The posting that's been flying around is old, it will come off soon. Its no biggie to me, I know what's happening, this is why newbies need to do their DD to find out the truth. The reasoning for the CE don't mean squat to me, very minor and it has been dealt with. Don't know what the hold up is for it to be gone like it should but like I said, its minor and really doesn't bother me, but it would benefit the pps, if they take the pos down...lol
In in big time at 0003, not budging.
Texas, Canada now NY. NOUV is huge. People are gonna be real surprised when this one starts moving. Its comming Mark it.
Give it time to sink in. Hemps legal in NY,. They brought acreage and now has a licence to produce. NOUV is involved with a lot of tickets, the sleeping giant.
Acreage and licenced... No brainer, top top it hemp is legal in N.Y.. Business start up right away.
ALYI Targets $100 Billion In Anticipated Investment Announcing New York Licensed Hemp Energy Storage Research Facility
Source: InvestorsHub NewsWire
ALYI Targets $100 Billion In Anticipated Investment Announcing New York Licensed Hemp Energy Storage Research Facility
Dallas, TX -- March 8, 2019 -- InvestorsHub NewsWire -- Alternet Systems, Inc. (USOTC: ALYI) (“ALYI”) today announced a license in the State of New York to grow hemp. The company has secured acreage in New York to grow and house the facility where hemp bast will be harvested for conducting further research within in the company’s hemp energy storage imitative. ALYI launched its hemp energy storage initiative late last year when the company brought Clarkson University Professor David Mitlin on board to lead a hemp energy storage initiative. Mitlin has successfully used hemp bast - the fiber left over from processing hemp - to construct carbon nanosheets that compete with, and in some respects, outperform the supercapacitor performance derived from more typical graphene nanosheets. Mitlin holds a US patent for his proprietary hemp energy storage technology.
?
Bloomberg New Energy Finance forecasts that the global energy storage market will “double six times” from 2017 levels to 2030, from than 5 gigawatt-hours last year, to more than 300 gigawatt-hours and 125 gigawatts of capacity by 2030. An estimated $103 billion will be invested in energy storage over that time period. ALYI management believes hemp energy storage is a strong candidate for receiving a fair portion of the anticipated investment.
ALYI has engaged the services of Nouveau (USOTC: NOUV) (“NOUV”) to manage the hemp farming operations. Puration, Inc. (USOTC: PURA) (“PURA”) recently spun-off its cannabis cultivation operation to NOUV.
Research Report Speculative Buy Rating And $0.09 Target PPS
Goldman Small Cap Research recently issued a research report update on the Company. The report confirms a 'speculative-buy' rating with a target price-per-share of $0.09. The report provides an in-depth overview and analysis of Alternet's new strategy, new orders, and upcoming milestones. To view the report, along with disclosures and disclaimers, visit https://www.alternetsystemsinc.com/research-update or http://www.GoldmanResearch.com.
ALYI is focused on offering varied, environmentally sustainable, energy storage solutions for targeted markets, including consumer electric vehicles and military applications. The first product category is lithium battery-powered motorcycles, to be followed by motorbikes. ALYI has recently announced $2 million in orders of its Revolt Electric Motorcycles. ALYI also recently brought Clarkson University Professor David Mitlin on board to lead a hemp energy storage initiative. Mitlin has successfully used hemp bast - the fiber left over from processing hemp - to construct carbon nanosheets that compete with, and in some respects, outperform the supercapacitor performance derived from more typical graphene nanosheets. Mitlin holds a US patent for his proprietary hemp energy storage technology.
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.
For more information, please visit: http://www.alternetsystemsinc.com
Alternet Systems, Inc. Contact:
Randell Torno
info@lithiumip.com
+1-800-713-0297
?
Busting through 14s today. It just gets better all the time.
Now were in NY. This is great.
ALYI Targets $100 Billion In Anticipated Investment Announcing New York Licensed Hemp Energy Storage Research Facility
Source: InvestorsHub NewsWire
ALYI Targets $100 Billion In Anticipated Investment Announcing New York Licensed Hemp Energy Storage Research Facility
Dallas, TX -- March 8, 2019 -- InvestorsHub NewsWire -- Alternet Systems, Inc. (USOTC: ALYI) (“ALYI”) today announced a license in the State of New York to grow hemp. The company has secured acreage in New York to grow and house the facility where hemp bast will be harvested for conducting further research within in the company’s hemp energy storage imitative. ALYI launched its hemp energy storage initiative late last year when the company brought Clarkson University Professor David Mitlin on board to lead a hemp energy storage initiative. Mitlin has successfully used hemp bast - the fiber left over from processing hemp - to construct carbon nanosheets that compete with, and in some respects, outperform the supercapacitor performance derived from more typical graphene nanosheets. Mitlin holds a US patent for his proprietary hemp energy storage technology.
?
Bloomberg New Energy Finance forecasts that the global energy storage market will “double six times” from 2017 levels to 2030, from than 5 gigawatt-hours last year, to more than 300 gigawatt-hours and 125 gigawatts of capacity by 2030. An estimated $103 billion will be invested in energy storage over that time period. ALYI management believes hemp energy storage is a strong candidate for receiving a fair portion of the anticipated investment.
ALYI has engaged the services of Nouveau (USOTC: NOUV) (“NOUV”) to manage the hemp farming operations. Puration, Inc. (USOTC: PURA) (“PURA”) recently spun-off its cannabis cultivation operation to NOUV.
Research Report Speculative Buy Rating And $0.09 Target PPS
Goldman Small Cap Research recently issued a research report update on the Company. The report confirms a 'speculative-buy' rating with a target price-per-share of $0.09. The report provides an in-depth overview and analysis of Alternet's new strategy, new orders, and upcoming milestones. To view the report, along with disclosures and disclaimers, visit https://www.alternetsystemsinc.com/research-update or http://www.GoldmanResearch.com.
ALYI is focused on offering varied, environmentally sustainable, energy storage solutions for targeted markets, including consumer electric vehicles and military applications. The first product category is lithium battery-powered motorcycles, to be followed by motorbikes. ALYI has recently announced $2 million in orders of its Revolt Electric Motorcycles. ALYI also recently brought Clarkson University Professor David Mitlin on board to lead a hemp energy storage initiative. Mitlin has successfully used hemp bast - the fiber left over from processing hemp - to construct carbon nanosheets that compete with, and in some respects, outperform the supercapacitor performance derived from more typical graphene nanosheets. Mitlin holds a US patent for his proprietary hemp energy storage technology.
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.
For more information, please visit: http://www.alternetsystemsinc.com
Alternet Systems, Inc. Contact:
Randell Torno
info@lithiumip.com
+1-800-713-0297
?
Generx has an contract with PURA and Kaly.
I'm looking at it this way, product is out, distributors like it and customers. If they can't keep up with demand, some bigger company that sees this will buy USCH out imo. Pura already has a million bottle goal.
Agree, I'm not going anywhere. This is going to get real good imo.
How long before we get out of this rut, and start trading like we should I wonder.
Ok POWER HOUR...lol let's see 6...lol
This is the update I'm looking for. This could be ground breaking news If in anyway this is a possibility. This will literally send us to orbit. D
Results due out any time shortly according to last update.
KALY - Kali-Extracts, Inc. Previews Pending Report On Cannabis Treatment For Lung Disease Study
Source: InvestorsHub NewsWire
?
KALY – Kali-Extracts, Inc. Previews Pending Report On Cannabis Treatment For Lung Disease Study
Dallas, TX -- February 21, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today published a second preview of a pending full report on their long-term, pilot study on the treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates with cannabis extracts derived from Kali-Extracts patented cannabis extraction process. The first preview was published on February 5, 2019. The full report is expected within the next 2 weeks. The primate study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients. The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.
The primate study was conducted by Professor Jeffry Osbourn, Ph.D., from the University of Kentucky and his Biomedical Science Research Group (BSRG). Professor Osbourn made the following statement in regard to the research adding to his original statement published on February 5th, 2019:
“We investigated the effects of a novel, new agent for the oral treatment of lung diseases like inflammation of the lung airways in nonhuman primates with chronic pulmonary fibrosis. The new NCM Biotech supplement was evaluated at 3 separate concentrations and compared to placebo treated animals. After only 2 weeks of daily oral treatment, a 5 fold dilution of the supplement extract increased respiration rate by 55%, airway flow rate by 82%, inspiratory airway flow velocity by 149%, and tidal volume by 38% compared to each animal’s own control values. Blood pressure and heart rate were not changed by the compound during this time frame. These large increases in pulmonary function in fibrotic lungs elicited marked increases in resting minute ventilation in these animals. A full report of the detailed data will be available within the next 2 weeks. Larger dilution (25 fold) had little to no effect on airway or lung functions. Further evaluation of this oral supplement is planned for determining the histological and gene regulatory changes in pulmonary airways, short and long term pharmacological compound distribution and renal/hepatic handling of the extract as well as molecular gas chromatography, mass spectroscopy assessment of the biologically active components. These future experiments are designed to more closely identify the mechanisms of this improved overall lung function leading to greatly improved life styles and activity levels for the large numbers of patients suffering from chronic pulmonary fibrosis.”
Kali-Extracts, Inc. (“KALY”) is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. KALY is utilizing is patented cannabis extraction process to develop numerous wellness products both internally and through partnerships. Similarly, KALY its patented cannabis extraction technology to develop pharmaceutical products internally and through partnerships.
KALY has licensed its extraction process to Puration, Inc. (USOTC: PURA) (“PURA”) for the production of beverages. With over $1 million in trailing twelve-month sales, PURA’s sales of EVERx CBD Sports Water are growing. KALY is now working with PURA to formulate a 25 MG CBD formula for a new CBD infused water product. Together, PURA and KALY have signed over a $1 million agreement to produce CBD infused water for Generex Biotechnology, Inc. (OTCBB: GNBT). The GNBT product is expected to be on shelves soon. The PURA and KALY agreement with GNBT is part of a larger agreement to explore potential pharmaceutical partnerships.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
5, 6, 5, 6, 5, 6..
Wth, this is worth way more.
Lol, more BS. We picked up distributors, more sales and going global. Looks like an up and up to me. This is the start, we are on the move, we will bust that goal of $5 million. Only fools would miss this one. Its a growing partnership and being proven. Looking forward to this play, will be here for a while.
Don't look like BS too me. Its the real deal, better get use to it. Huge move comming.
PURA - Puration Signs New CBD Beverage Distribution Orders With Even Bigger Orders Underway Fueling M&A Interest
Source: InvestorsHub NewsWire
PURA - Puration Signs New CBD Beverage Distribution Orders With Even Bigger Orders Underway Fueling M&A Interest
Dallas, TX -- March 7, 2019 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) today published a presentation, to review new orders, opportunities and partnerships stemming from the EVERx CBD Sports Water event this past weekend at the Arnold Sports Festival. EVERx CBD Sports Water debuted it’s all new formula and packaging at the world-renowned Arnold Sports Festival this week in Columbus, Ohio where EVERx launched for the first time ever in 2017. PURA comes away from the Arnold with signed new orders supporting the company’s 2019 $5 million revenue goal. As a result of the Arnold event, PURA also now enjoys the potential for new orders from notable and substantial distributors, new partnerships that will accelerate PURA’s global reach, and new opportunities specifically in the form of heightened merger and acquisition (M&A) interest. PURA sent five times the amount of EVERx to the Arnold than ever before supplied in the previous two years at the Arnold and still ran out of EVERx before the end of the event. Management attributes the new sales, marketing partnership and M&A opportunities to the increased interest in cannabis products, particularly CBD, since 1. the legalization of recreational marijuana in Canada and 2. the legalization of hemp farming in the United States under the 2018 Farm Act.
?
EVERx Sales Growth
EVERx is the leading CBD beverage in the sports nutrition market place. It’s presence at the Arnold has grown over the last three years to monumental proportions this year. There is no better place for EVERx to be exposed to distributors in the sports nutrition market place. The largest distributors in the industry are sponsors at the Arnold. EVERx won the interest of gym chains, sports nutrition distributors and mega food and beverage distributors with a sports nutrition segment. PURA came away from the Arnold with signed new orders and two mega distributors beginning due diligence on PURA’s EVERx beverage. Management plans to make independent announcements in the coming days and weeks about each new sales contract in addition to elaborating on the due diligence progress with the two mega distributors.
PURA recently announced that the company has partnered with North American Cannabis Holdings, Inc.(USOTC: USMJ) (“USMJ”) to add a B2B eCommerce function onto USMJ’s recently launched consumer eCommerce site at www.USMJ.com. The B2B eCommerce function will launch first to provide buyers with the ability to make wholesale purchases of PURA’s EVERx CBD Sports Water. PURA has licensed a major customer relationship management (CRM) software solution to build a cannabis industry big data capacity into USMJ’s eCommerce site. The CRM empowered cannabis wholesale buyer and retail consumer big data analytics capacity is designed to position USMJ.com as the preeminent cannabis industry online marketplace. The B2B eCommerce site is currently being pilot tested and expected to go live imminently. The B2B launch announcement will include details on the CRM solution and big data capacity.
EVERx Marketing and Brand Building
The Arnold Sports Festival is the leading venue for sports nutrition products around the world. In addition to the annual event in Columbus, Ohio, the Arnold Sports Festival has annual events in Australia, South America, Africa and Europe. In addition to continuing to expand the EVERx brand through the annual Arnold Sports Festival in the United States, PURA will here forward be a part of the Arnold Sports Festival globally. Look for an upcoming announcement about EVERx at its next Arnold Sports Festival event.
PURA Product Development
PURA has licensed a patented cannabis extraction process from Kali-Extracts (USOTC: KALY) (“KALY”) for use in its beverages. PURA and KALY are working closely together on the development of a CBD infused beverage with 25 mg of CBD. The general industry standard in the beverage industry is 5 mg. PURA’s EVERx is already ahead of most of the industry with 10 mg of CBD. PURA and KALY have been contracted by Generex Biotechnology (OTCBB: GNBT) to produce a private label water under a Generex brand name. A 10mg water is in production. In the meantime, PURA and KALY are working together to introduce a 25 mg version of the Generex private label product.
PURA has more beverages in addition to EVERx starting to hit shelves now. Look for announcements coming soon.
PURA M&A
The legalization of recreational marijuana in Canada last year and the recent legalization of hemp farming in the United States has ignited the market for cannabis investments in addition to heating up the M&A market for cannabis enterprises. The M&A activities of Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE: ACB) makes almost daily news. CBD infused beverages are topping the list of M&A candidates and PURA’s success with EVERx has pushed PURA to the top of numerous target M&A lists. PURA’s visibility at the Arnold has moved PURA even further up those target M&A lists. CEO Brian Shibley reports that “hardly a day goes by where we do not receive an M&A inquiry.” The company has only so far entertained two of the inquiries, one on behalf of a prominent beverage industry player, and one from a competitor. Mr. Shibley reports PURA is also looking at acquisitions of its own. “We have introduced to our co-packer partner the idea of their company being acquired by PURA.” The co-packer acquisition is only a conversation at this stage with more ground to be covered before a formal offer would be advanced, but Mr. Shibley reports, “we are keen on the idea at this moment.”
Analyst Speculative Buy Recommendation and $0.25 PPS Target with $0.35 Upside
Goldman Small Cap Research issued a research update on Puration, Inc. (USOTC: PURA) last week recommending a 'speculative-buy' rating with a target price-per-share of $0.25, with noted potential upside to the $0.35 mark.
For more information on Puration, and to visit more photos taken at the recent Arnold Sports Festival, visit http://www.purationinc.com/pura-2019-post-arnold-presentation">http://www.http://www.purationinc.com/pura-2019-post-arnold-presentation">purationinc.com/pura-2019-post-arnold-presentation" rel="nofollow" target="_blank">
??
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
WE ARE THE CULTIVATOR FOR PURA AND KALY. REMEMBER THIS.
PURA - Puration Signs New CBD Beverage Distribution Orders With Even Bigger Orders Underway Fueling M&A Interest
Source: InvestorsHub NewsWire
PURA - Puration Signs New CBD Beverage Distribution Orders With Even Bigger Orders Underway Fueling M&A Interest
Dallas, TX -- March 7, 2019 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) today published a presentation, to review new orders, opportunities and partnerships stemming from the EVERx CBD Sports Water event this past weekend at the Arnold Sports Festival. EVERx CBD Sports Water debuted it’s all new formula and packaging at the world-renowned Arnold Sports Festival this week in Columbus, Ohio where EVERx launched for the first time ever in 2017. PURA comes away from the Arnold with signed new orders supporting the company’s 2019 $5 million revenue goal. As a result of the Arnold event, PURA also now enjoys the potential for new orders from notable and substantial distributors, new partnerships that will accelerate PURA’s global reach, and new opportunities specifically in the form of heightened merger and acquisition (M&A) interest. PURA sent five times the amount of EVERx to the Arnold than ever before supplied in the previous two years at the Arnold and still ran out of EVERx before the end of the event. Management attributes the new sales, marketing partnership and M&A opportunities to the increased interest in cannabis products, particularly CBD, since 1. the legalization of recreational marijuana in Canada and 2. the legalization of hemp farming in the United States under the 2018 Farm Act.
?
EVERx Sales Growth
EVERx is the leading CBD beverage in the sports nutrition market place. It’s presence at the Arnold has grown over the last three years to monumental proportions this year. There is no better place for EVERx to be exposed to distributors in the sports nutrition market place. The largest distributors in the industry are sponsors at the Arnold. EVERx won the interest of gym chains, sports nutrition distributors and mega food and beverage distributors with a sports nutrition segment. PURA came away from the Arnold with signed new orders and two mega distributors beginning due diligence on PURA’s EVERx beverage. Management plans to make independent announcements in the coming days and weeks about each new sales contract in addition to elaborating on the due diligence progress with the two mega distributors.
PURA recently announced that the company has partnered with North American Cannabis Holdings, Inc.(USOTC: USMJ) (“USMJ”) to add a B2B eCommerce function onto USMJ’s recently launched consumer eCommerce site at www.USMJ.com. The B2B eCommerce function will launch first to provide buyers with the ability to make wholesale purchases of PURA’s EVERx CBD Sports Water. PURA has licensed a major customer relationship management (CRM) software solution to build a cannabis industry big data capacity into USMJ’s eCommerce site. The CRM empowered cannabis wholesale buyer and retail consumer big data analytics capacity is designed to position USMJ.com as the preeminent cannabis industry online marketplace. The B2B eCommerce site is currently being pilot tested and expected to go live imminently. The B2B launch announcement will include details on the CRM solution and big data capacity.
EVERx Marketing and Brand Building
The Arnold Sports Festival is the leading venue for sports nutrition products around the world. In addition to the annual event in Columbus, Ohio, the Arnold Sports Festival has annual events in Australia, South America, Africa and Europe. In addition to continuing to expand the EVERx brand through the annual Arnold Sports Festival in the United States, PURA will here forward be a part of the Arnold Sports Festival globally. Look for an upcoming announcement about EVERx at its next Arnold Sports Festival event.
PURA Product Development
PURA has licensed a patented cannabis extraction process from Kali-Extracts (USOTC: KALY) (“KALY”) for use in its beverages. PURA and KALY are working closely together on the development of a CBD infused beverage with 25 mg of CBD. The general industry standard in the beverage industry is 5 mg. PURA’s EVERx is already ahead of most of the industry with 10 mg of CBD. PURA and KALY have been contracted by Generex Biotechnology (OTCBB: GNBT) to produce a private label water under a Generex brand name. A 10mg water is in production. In the meantime, PURA and KALY are working together to introduce a 25 mg version of the Generex private label product.
PURA has more beverages in addition to EVERx starting to hit shelves now. Look for announcements coming soon.
PURA M&A
The legalization of recreational marijuana in Canada last year and the recent legalization of hemp farming in the United States has ignited the market for cannabis investments in addition to heating up the M&A market for cannabis enterprises. The M&A activities of Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE: ACB) makes almost daily news. CBD infused beverages are topping the list of M&A candidates and PURA’s success with EVERx has pushed PURA to the top of numerous target M&A lists. PURA’s visibility at the Arnold has moved PURA even further up those target M&A lists. CEO Brian Shibley reports that “hardly a day goes by where we do not receive an M&A inquiry.” The company has only so far entertained two of the inquiries, one on behalf of a prominent beverage industry player, and one from a competitor. Mr. Shibley reports PURA is also looking at acquisitions of its own. “We have introduced to our co-packer partner the idea of their company being acquired by PURA.” The co-packer acquisition is only a conversation at this stage with more ground to be covered before a formal offer would be advanced, but Mr. Shibley reports, “we are keen on the idea at this moment.”
Analyst Speculative Buy Recommendation and $0.25 PPS Target with $0.35 Upside
Goldman Small Cap Research issued a research update on Puration, Inc. (USOTC: PURA) last week recommending a 'speculative-buy' rating with a target price-per-share of $0.25, with noted potential upside to the $0.35 mark.
For more information on Puration, and to visit more photos taken at the recent Arnold Sports Festival, visit http://www.purationinc.com/pura-2019-post-arnold-presentation">http://www.http://www.purationinc.com/pura-2019-post-arnold-presentation">purationinc.com/pura-2019-post-arnold-presentation" rel="nofollow" target="_blank">
??
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
PURA - Puration Signs New CBD Beverage Distribution Orders With Even Bigger Orders Underway Fueling M&A Interest
Source: InvestorsHub NewsWire
PURA - Puration Signs New CBD Beverage Distribution Orders With Even Bigger Orders Underway Fueling M&A Interest
Dallas, TX -- March 7, 2019 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) today published a presentation, to review new orders, opportunities and partnerships stemming from the EVERx CBD Sports Water event this past weekend at the Arnold Sports Festival. EVERx CBD Sports Water debuted it’s all new formula and packaging at the world-renowned Arnold Sports Festival this week in Columbus, Ohio where EVERx launched for the first time ever in 2017. PURA comes away from the Arnold with signed new orders supporting the company’s 2019 $5 million revenue goal. As a result of the Arnold event, PURA also now enjoys the potential for new orders from notable and substantial distributors, new partnerships that will accelerate PURA’s global reach, and new opportunities specifically in the form of heightened merger and acquisition (M&A) interest. PURA sent five times the amount of EVERx to the Arnold than ever before supplied in the previous two years at the Arnold and still ran out of EVERx before the end of the event. Management attributes the new sales, marketing partnership and M&A opportunities to the increased interest in cannabis products, particularly CBD, since 1. the legalization of recreational marijuana in Canada and 2. the legalization of hemp farming in the United States under the 2018 Farm Act.
?
EVERx Sales Growth
EVERx is the leading CBD beverage in the sports nutrition market place. It’s presence at the Arnold has grown over the last three years to monumental proportions this year. There is no better place for EVERx to be exposed to distributors in the sports nutrition market place. The largest distributors in the industry are sponsors at the Arnold. EVERx won the interest of gym chains, sports nutrition distributors and mega food and beverage distributors with a sports nutrition segment. PURA came away from the Arnold with signed new orders and two mega distributors beginning due diligence on PURA’s EVERx beverage. Management plans to make independent announcements in the coming days and weeks about each new sales contract in addition to elaborating on the due diligence progress with the two mega distributors.
PURA recently announced that the company has partnered with North American Cannabis Holdings, Inc.(USOTC: USMJ) (“USMJ”) to add a B2B eCommerce function onto USMJ’s recently launched consumer eCommerce site at www.USMJ.com. The B2B eCommerce function will launch first to provide buyers with the ability to make wholesale purchases of PURA’s EVERx CBD Sports Water. PURA has licensed a major customer relationship management (CRM) software solution to build a cannabis industry big data capacity into USMJ’s eCommerce site. The CRM empowered cannabis wholesale buyer and retail consumer big data analytics capacity is designed to position USMJ.com as the preeminent cannabis industry online marketplace. The B2B eCommerce site is currently being pilot tested and expected to go live imminently. The B2B launch announcement will include details on the CRM solution and big data capacity.
EVERx Marketing and Brand Building
The Arnold Sports Festival is the leading venue for sports nutrition products around the world. In addition to the annual event in Columbus, Ohio, the Arnold Sports Festival has annual events in Australia, South America, Africa and Europe. In addition to continuing to expand the EVERx brand through the annual Arnold Sports Festival in the United States, PURA will here forward be a part of the Arnold Sports Festival globally. Look for an upcoming announcement about EVERx at its next Arnold Sports Festival event.
PURA Product Development
PURA has licensed a patented cannabis extraction process from Kali-Extracts (USOTC: KALY) (“KALY”) for use in its beverages. PURA and KALY are working closely together on the development of a CBD infused beverage with 25 mg of CBD. The general industry standard in the beverage industry is 5 mg. PURA’s EVERx is already ahead of most of the industry with 10 mg of CBD. PURA and KALY have been contracted by Generex Biotechnology (OTCBB: GNBT) to produce a private label water under a Generex brand name. A 10mg water is in production. In the meantime, PURA and KALY are working together to introduce a 25 mg version of the Generex private label product.
PURA has more beverages in addition to EVERx starting to hit shelves now. Look for announcements coming soon.
PURA M&A
The legalization of recreational marijuana in Canada last year and the recent legalization of hemp farming in the United States has ignited the market for cannabis investments in addition to heating up the M&A market for cannabis enterprises. The M&A activities of Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE: ACB) makes almost daily news. CBD infused beverages are topping the list of M&A candidates and PURA’s success with EVERx has pushed PURA to the top of numerous target M&A lists. PURA’s visibility at the Arnold has moved PURA even further up those target M&A lists. CEO Brian Shibley reports that “hardly a day goes by where we do not receive an M&A inquiry.” The company has only so far entertained two of the inquiries, one on behalf of a prominent beverage industry player, and one from a competitor. Mr. Shibley reports PURA is also looking at acquisitions of its own. “We have introduced to our co-packer partner the idea of their company being acquired by PURA.” The co-packer acquisition is only a conversation at this stage with more ground to be covered before a formal offer would be advanced, but Mr. Shibley reports, “we are keen on the idea at this moment.”
Analyst Speculative Buy Recommendation and $0.25 PPS Target with $0.35 Upside
Goldman Small Cap Research issued a research update on Puration, Inc. (USOTC: PURA) last week recommending a 'speculative-buy' rating with a target price-per-share of $0.25, with noted potential upside to the $0.35 mark.
For more information on Puration, and to visit more photos taken at the recent Arnold Sports Festival, visit http://www.purationinc.com/pura-2019-post-arnold-presentation">http://www.http://www.purationinc.com/pura-2019-post-arnold-presentation">purationinc.com/pura-2019-post-arnold-presentation" rel="nofollow" target="_blank">
??
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
Exspecting a pop, such bull going on, on this board. Let the freaking ticker ride already.
Really wish he would get off the shutter and give us an update/news. Getting tired watching, 5,6,5,6,5,6,5,6... Lets pick it up a few knoches already.
I hope your wrong on that. If this is proven, it will be very, very big. Its a far fetch, but if there's a chance it works for COPD we will be rich.
Just a reminder.
KALY - Kali-Extracts, Inc. Previews Pending Report On Cannabis Treatment For Lung Disease Study
Source: InvestorsHub NewsWire
?
KALY – Kali-Extracts, Inc. Previews Pending Report On Cannabis Treatment For Lung Disease Study
Dallas, TX -- February 21, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today published a second preview of a pending full report on their long-term, pilot study on the treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates with cannabis extracts derived from Kali-Extracts patented cannabis extraction process. The first preview was published on February 5, 2019. The full report is expected within the next 2 weeks. The primate study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients. The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.
The primate study was conducted by Professor Jeffry Osbourn, Ph.D., from the University of Kentucky and his Biomedical Science Research Group (BSRG). Professor Osbourn made the following statement in regard to the research adding to his original statement published on February 5th, 2019:
“We investigated the effects of a novel, new agent for the oral treatment of lung diseases like inflammation of the lung airways in nonhuman primates with chronic pulmonary fibrosis. The new NCM Biotech supplement was evaluated at 3 separate concentrations and compared to placebo treated animals. After only 2 weeks of daily oral treatment, a 5 fold dilution of the supplement extract increased respiration rate by 55%, airway flow rate by 82%, inspiratory airway flow velocity by 149%, and tidal volume by 38% compared to each animal’s own control values. Blood pressure and heart rate were not changed by the compound during this time frame. These large increases in pulmonary function in fibrotic lungs elicited marked increases in resting minute ventilation in these animals. A full report of the detailed data will be available within the next 2 weeks. Larger dilution (25 fold) had little to no effect on airway or lung functions. Further evaluation of this oral supplement is planned for determining the histological and gene regulatory changes in pulmonary airways, short and long term pharmacological compound distribution and renal/hepatic handling of the extract as well as molecular gas chromatography, mass spectroscopy assessment of the biologically active components. These future experiments are designed to more closely identify the mechanisms of this improved overall lung function leading to greatly improved life styles and activity levels for the large numbers of patients suffering from chronic pulmonary fibrosis.”
Kali-Extracts, Inc. (“KALY”) is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. KALY is utilizing is patented cannabis extraction process to develop numerous wellness products both internally and through partnerships. Similarly, KALY its patented cannabis extraction technology to develop pharmaceutical products internally and through partnerships.
KALY has licensed its extraction process to Puration, Inc. (USOTC: PURA) (“PURA”) for the production of beverages. With over $1 million in trailing twelve-month sales, PURA’s sales of EVERx CBD Sports Water are growing. KALY is now working with PURA to formulate a 25 MG CBD formula for a new CBD infused water product. Together, PURA and KALY have signed over a $1 million agreement to produce CBD infused water for Generex Biotechnology, Inc. (OTCBB: GNBT). The GNBT product is expected to be on shelves soon. The PURA and KALY agreement with GNBT is part of a larger agreement to explore potential pharmaceutical partnerships.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Nice buys hitting. Follow the yellow brick road.
My thoughts to the T. Thank you
I didn't disagree charts aren't good to watch, and try to predict movements. I read charts all the time, predictions are based off analysis, and indicators. Which I find may lead to thinking a uptrend is comming which can also turn into a dip. I said I would rather buy on where the company is heading off news/updates, buy on dips and sell on news, or hold for a longer investment. I see it you can look at charts and spot trends which help with long term investing. If your looking to flip yeah reading indicators can sometimes let you know when too. I know about charts but rely more on company news and updates. I'm not saying there a bad thing, just I'm long and evaluate the company on morning forward, not the daily pps.
I think it would be called an update, not a paid bump. Do you realize how big a break through this would be?
Prove they don't have none. They proved they did. Where's your proof?
Comming up anytime now. This may set Kaly on fire with good results.
KALY - Kali-Extracts, Inc. Previews Pending Report On Cannabis Treatment For Lung Disease Study
Source: InvestorsHub NewsWire
?
KALY – Kali-Extracts, Inc. Previews Pending Report On Cannabis Treatment For Lung Disease Study
Dallas, TX -- February 21, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today published a second preview of a pending full report on their long-term, pilot study on the treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates with cannabis extracts derived from Kali-Extracts patented cannabis extraction process. The first preview was published on February 5, 2019. The full report is expected within the next 2 weeks. The primate study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients. The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.
The primate study was conducted by Professor Jeffry Osbourn, Ph.D., from the University of Kentucky and his Biomedical Science Research Group (BSRG). Professor Osbourn made the following statement in regard to the research adding to his original statement published on February 5th, 2019:
“We investigated the effects of a novel, new agent for the oral treatment of lung diseases like inflammation of the lung airways in nonhuman primates with chronic pulmonary fibrosis. The new NCM Biotech supplement was evaluated at 3 separate concentrations and compared to placebo treated animals. After only 2 weeks of daily oral treatment, a 5 fold dilution of the supplement extract increased respiration rate by 55%, airway flow rate by 82%, inspiratory airway flow velocity by 149%, and tidal volume by 38% compared to each animal’s own control values. Blood pressure and heart rate were not changed by the compound during this time frame. These large increases in pulmonary function in fibrotic lungs elicited marked increases in resting minute ventilation in these animals. A full report of the detailed data will be available within the next 2 weeks. Larger dilution (25 fold) had little to no effect on airway or lung functions. Further evaluation of this oral supplement is planned for determining the histological and gene regulatory changes in pulmonary airways, short and long term pharmacological compound distribution and renal/hepatic handling of the extract as well as molecular gas chromatography, mass spectroscopy assessment of the biologically active components. These future experiments are designed to more closely identify the mechanisms of this improved overall lung function leading to greatly improved life styles and activity levels for the large numbers of patients suffering from chronic pulmonary fibrosis.”
Kali-Extracts, Inc. (“KALY”) is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. KALY is utilizing is patented cannabis extraction process to develop numerous wellness products both internally and through partnerships. Similarly, KALY its patented cannabis extraction technology to develop pharmaceutical products internally and through partnerships.
KALY has licensed its extraction process to Puration, Inc. (USOTC: PURA) (“PURA”) for the production of beverages. With over $1 million in trailing twelve-month sales, PURA’s sales of EVERx CBD Sports Water are growing. KALY is now working with PURA to formulate a 25 MG CBD formula for a new CBD infused water product. Together, PURA and KALY have signed over a $1 million agreement to produce CBD infused water for Generex Biotechnology, Inc. (OTCBB: GNBT). The GNBT product is expected to be on shelves soon. The PURA and KALY agreement with GNBT is part of a larger agreement to explore potential pharmaceutical partnerships.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Whatever. I'm in and hanging long. I know what I own, its a sure thing. Peeps do not sway my investments, we have a patent product, its producing, and profits will be had for all. If your so hellbent on this not making it, why are you here everyday accumulating, or are you making washes of the negativity?.